The impact of gene profiling in chronic myeloid leukaemia
- PMID: 19698927
- DOI: 10.1016/j.beha.2009.04.002
The impact of gene profiling in chronic myeloid leukaemia
Abstract
The use of microarray technology in chronic myeloid leukaemia (CML) has increased our understanding of the biology of this disease. From early studies of gene expression profiling in BCR-ABL-positive cell lines to samples from patients in different disease phases of CML, using resting cells or cells treated with a variety of therapeutic agents, the field has now moved on to profiling microRNA and single nucleotide polymorphisms of CML cells. With the advent of tyrosine kinase inhibitors, several groups have also attempted to use microarray profiling to ascertain if particular gene expression profiles pre-existing in patients' CML cells, which could reflect intrinsic disease biology, would predict for response to treatment. This could streamline patients for alternative treatments upfront should a poor risk profile be found. In this article, we provide an overview of the progress made so far in this field, and outline the more substantial results of available microarray studies to date.
Similar articles
-
Role of gene-expression profiling in chronic myeloid leukemia.Expert Rev Hematol. 2009 Feb;2(1):93-103. doi: 10.1586/17474086.2.1.93. Expert Rev Hematol. 2009. PMID: 21082998 Review.
-
Meta-analysis of microarray data: The case of imatinib resistance in chronic myelogenous leukemia.Comput Biol Chem. 2010 Jun;34(3):184-92. doi: 10.1016/j.compbiolchem.2010.06.003. Epub 2010 Jun 18. Comput Biol Chem. 2010. PMID: 20619742
-
New targets for Ph+ leukaemia therapy.Best Pract Res Clin Haematol. 2009 Sep;22(3):445-54. doi: 10.1016/j.beha.2009.08.002. Best Pract Res Clin Haematol. 2009. PMID: 19959093 Review.
-
Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.Acta Haematol. 2009;122(1):11-6. doi: 10.1159/000230037. Epub 2009 Jul 29. Acta Haematol. 2009. PMID: 19641300
-
Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.Cancer Cell. 2009 Sep 8;16(3):174-6. doi: 10.1016/j.ccr.2009.08.012. Cancer Cell. 2009. PMID: 19732715
Cited by
-
Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients.Cancers (Basel). 2020 Dec 11;12(12):3738. doi: 10.3390/cancers12123738. Cancers (Basel). 2020. PMID: 33322625 Free PMC article.
-
Biomarkers for determining the prognosis in chronic myelogenous leukemia.J Hematol Oncol. 2013 Jul 19;6:54. doi: 10.1186/1756-8722-6-54. J Hematol Oncol. 2013. PMID: 23870290 Free PMC article. Review.
-
Chronic myeloid leukemia: mechanisms of blastic transformation.J Clin Invest. 2010 Jul;120(7):2254-64. doi: 10.1172/JCI41246. Epub 2010 Jul 1. J Clin Invest. 2010. PMID: 20592475 Free PMC article. Review.
-
Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samples.J Mol Diagn. 2013 May;15(3):391-400. doi: 10.1016/j.jmoldx.2013.02.004. Epub 2013 Mar 27. J Mol Diagn. 2013. PMID: 23541592 Free PMC article.
-
Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.Med Oncol. 2014 Mar;31(3):851. doi: 10.1007/s12032-014-0851-5. Epub 2014 Jan 29. Med Oncol. 2014. PMID: 24469953
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous